{"url_path":"/sec/ibio/8-k/2026-07-01/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 **     **Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1420720/0001420720-26-000010-index.html","accession_number":"0001420720-26-000010","cik":"0001420720","ticker":"IBIO","issuer_name":"iBio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1420720/0001420720-26-000010-index.html","primary_entity_key":"0001420720","primary_entity_name":"iBio, Inc."},"word_count":355,"has_tables":true,"body_markdown":"**Item 7.01.**     **Regulation FD Disclosure.**\n\n \n\nOn July 1, 2026, iBio, Inc. (the “Company”) issued a press release announcing new preclinical data from its obese non-human primate (“NHP”) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate.\n\nFollowing a single dose of IBIO-610, active Activin E levels in the blood were reduced in all treated NHPs and remained suppressed through eight weeks. At both weeks 4 and 8, active Activin E levels were reduced to levels below the limits of the assay. Overall, active Activin E was reduced by 98% at week 4 and 97% at week 8 compared with baseline. These findings support IBIO-610's potential for best-in-class pathway inhibition and further support the potential for an infrequently dosed, long-acting antibody approach.\n\nThe data also demonstrated IBIO-610's potential to promote fat-selective weight loss while preserving lean mass. In obese NHPs, when combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone, further supporting its potential as both a stand-alone therapy and a complementary approach to GLP-1-based treatments.\n\nThe full data will be highlighted in a presentation at the 62nd Annual Meeting of the European Association for the Study of Diabetes, taking place September 28 – October 2 in Milan.\n\nThe information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.\n\n​"}